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OBJECTIVES This phase I study was designed to evaluate the safety, tolerability and pharmacokinetics of
intra-arterial basic fibroblast growth factor (bFGF) in patients with atherosclerotic peripheral
arterial disease (PVD) and intermittent claudication. We also assessed the effects of basic
fibroblast growth factor (bFGF) on calf blood flow as a measure of biologic activity.
BACKGROUND Preclinical studies have shown that bFGF, an angiogenic peptide, promotes collateral
development in animal models of myocardial and hind limb ischemia. The safety and efficacy
of bFGF in patients is unknown, and early clinical trials are underway in coronary and
peripheral arterial disease.
METHODS A double-blind, placebo-controlled, dose-escalation trial was conducted in patients with
claudication demonstrating ankle/brachial index ,0.8. Patients were randomly assigned to
placebo (n 5 6), 10 mg/kg of bFGF (n 5 4), 30 mg/kg of bFGF once (n 5 5) and 30 mg/kg
of bFGF on two consecutive days (n 5 4). Study drug was infused into the femoral artery of
the ischemic leg. Detailed safety information including retinal photography for neovascular-
ization were obtained through one year. Calf blood flow was measured with strain gauge
plethysmography in the two higher dose treatment groups and in four placebo patients at
baseline, one month and three to seven months after treatment.
RESULTS Intra-arterial bFGF was safe and well-tolerated. The half-life was 46 6 21 min. Calf blood
flow increased at one month by 66 6 26% (mean 6 SEM) and at six months by 153 6 51%
in bFGF-treated patients (n 5 9, p 5 0.002). Flow did not change significantly in the placebo
group.
CONCLUSIONS In this initial randomized, double-blind, placebo-controlled trial in patients with atheroscle-
rotic PVD and claudication, bFGF was well-tolerated. The data suggest a salutary biologic
effect, and initiation of phase 2 trials is warranted. (J Am Coll Cardiol 2000;36:1239–44) ©
2000 by the American College of Cardiology
Peripheral arterial disease (PVD) is a significant public
health problem (1) for which pharmacologic therapies have
not been consistently effective (2). In older adults, a strong
association exists between intermittent claudication and
subsequent mortality and cardiovascular morbidity (3–5).
Recently, significant research has focused on developing
angiogenic therapies to provide novel approaches to the
treatment of myocardial and limb ischemia. We and other
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investigators have demonstrated the potential of basic fibro-
blast growth factor (bFGF) to improve collateral develop-
ment in animal models of myocardial (6–9) and hind limb
(10–12) ischemia. On the basis of these findings, we
initiated a phase I trial to evaluate the safety, tolerability and
pharmacokinetics of intra-arterial bFGF in patients with
atherosclerotic PVD and intermittent claudication. We also
assessed the effects of bFGF on calf blood flow as a measure
of biologic activity.
METHODS
Patient population. Selection criteria included age .40
years, a history of intermittent claudication for .6 months
and ankle brachial index (ABI) ,0.8 at rest or after 5 min
of standardized exercise (13) (2 miles per h at a grade of
10°).
Exclusion criteria included gangrene, osteomyelitis, vas-
cular interventions within three months of enrollment,
serum creatinine .2.0 mg/dL, significant proteinuria, pre-
existing or suspected malignancy and severe nonproliferative
or proliferative diabetic retinopathy.
The study was performed at the National Heart, Lung,
and Blood Institute, Bethesda, Maryland, and was approved
by the Institutional Review Board. An independent Data
Safety Monitoring Board monitored the safety of the drug.
Nineteen patients met the total study criteria and were
randomized after giving written informed consent.
Study protocol. At enrollment, a medical history and
physical examination were conducted. Clinical laboratory
studies were performed at screening (complete blood count,
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blood chemical analyses, urinalysis, 24-h urine for total
protein and creatinine clearance) and repeated three days
and one, two and four weeks after treatment. Screening tests
for occult malignancy included chest X-ray, prostate specific
antigen in men, mammogram, pelvic examination/pap
smear in women and stool for occult blood. Comprehensive
ophthalmologic examination, including retinal photography
of the seven standard stereoscopic fields, was performed at
baseline, one, three and 12 months. Patients answered a
questionnaire with a review of systems, which included
grading the degree of claudication as being the same, better
or worse than usual. Exercise testing for measurement of
ABI was performed using a treadmill speed of 2 miles per h
at a 10° grade. Patients were required to be on a stable
medication regimen six weeks before entry into the study
and during the follow-up period.
Basic fibroblast growth factor was provided by Scios, Inc.,
Mountainview, California. Nineteen subjects were ran-
domly assigned to bFGF, 10 mg/kg injected once, 30 mg/kg
injected once or 30 mg/kg injected twice (on consecutive
days). Randomization was in blocks of six, with two and
four subjects assigned to placebo and bFGF, respectively.
One patient randomized to bFGF 32 doses did not receive
the second dose, because of thrombocytopenia (decrease in
platelet count from 150,000 to 120,000), and follow-up data
from this patient are included with the 30 mg/kg 31 group.
Patients were hydrated with 500 mL of normal saline
before study drug administration, and hydration was main-
tained at 60 to 75 mL per hour for 4 h after drug infusion.
The femoral artery of the more ischemic leg, as determined
by ABI, was cannulated percutaneously with an 18 gauge
catheter (Arrow International, Inc. Reading, Pennsylvania),
and the study agent was administered by intra-arterial
infusion over 15 min. Heparin was not used. Hemodynamic
monitoring was performed for 30 min after infusion. All
patients underwent continuous Holter monitoring from the
time of initial drug infusion to 36 h after the second
treatment.
Venous blood samples were assayed for human bFGF at
0, 1, 3, 5, 10, 20, 30, 60, 120 and 180 min using a
solid-phase ELISA kit (catalog No.DFB00, R&D Systems,
Inc., Minneapolis, Minnesota) by Burleson Research Tech-
nologies, Inc., Raleigh, North Carolina.
Measurement of calf blood flow. After completion of the
1 month safety follow-up in the first block of patients
(10 mg/kg bFGF), we amended the study protocol to assess
possible effects of bFGF on lower extremity blood flow.
These measurements were carried out in the two high-dose
bFGF groups using strain gauge plethysmography (Hokan-
son, Issaquah, Washington), as previously described (14).
Measurements were made immediately before treatment, at
1 month and at 3 to 7 months (median 6 months) after
treatment by an observer blinded to group assignment.
Statistical analysis. Data are expressed as mean 6 SEM
unless stated otherwise. For the analysis of pre- versus
posttreatment differences, Friedman repeated measures
analysis of variance on ranks was used. A p value ,0.05 was
considered to indicate statistical significance. Correction for
pairwise multiple comparisons was made using the Student-
Newman-Keuls method.
RESULTS
Patients. Baseline patient characteristics are summarized in
Table 1. There were a number of imbalances in baseline
characteristics, typical of a study of limited sample size.
Safety. The first subject randomized to bFGF received a
10 mg/kg bolus over 2 min. Systolic blood pressure de-
creased by 22% at 1 min and by 47% at 20 min, with onset
of recovery at 25 min and return to baseline by 60 min,
aided by infusion of saline. The patient remained asymp-
tomatic. For subsequent subjects, the protocol was modified
to deliver the study agent using an infusion pump over 4 min
in the 10 mg/kg group and over 15 min in the 30 mg/kg group,
and significant hypotension was not observed.
Retinal neovascularization was not detected during the
course of the study. Mild transient proteinuria occurred in
both placebo and bFGF-treated subjects, but there were no
significant differences between groups in any hematological
or biochemical tests. One patient age 74 with borderline
thrombocytopenia ranging between 145,000 and 150,000/
mm3 developed a platelet count of 124,000/mm3 24 h after
treatment with one dose 30 mg/kg of bFGF, with recovery
to baseline in five days. Atrial fibrillation also occurred in
this patient, who had no prior history of arrhythmia, 72 h
after receiving 30 mg/kg of bFGF. Spontaneous conversion
to sinus rhythm occurred 12 h later.
Abbreviations and Acronyms
ABI 5 ankle/brachial index or systolic blood pressure
ratio
bFGF 5 basic fibroblast growth factor
PVD 5 peripheral arterial disease
VEGF 5 vascular endothelial growth factor
Table 1. Characteristics of bFGF Treated and Placebo Patients:
Baseline Demographics and Disease Status
Parameters bFGF-treated Placebo
Number of subjects 13 6
Age, years 68 6 10 77 6 9
Men 6 4
Diabetes 2 3
Smokers 5 1
Hypertension 6 5
Previous vascular surgery 4 0
Previous lower limb PTA 4 3
H/o CAD/CABG 4 2
Cholesterol (mg/dL) 215 6 55 181 6 19
Baseline ABI 0.60 6 0.28 0.71 6 0.34
Values are means 6 SD.
ABI 5 ankle/brachial systolic blood pressure ratio; bFGF 5 basic fibroblast
growth factor; CABG 5 coronary artery bypass grafting; CAD 5 coronary artery
disease; H/o 5 history of; PTA 5 percutaneous transluminal angioplasty.
To convert values for cholesterol to mmol/L, multiply by 0.0259.
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Pharmacokinetics of bFGF. Serum bFGF levels peaked at
1 min after infusion. Basic fibroblast growth factor had a
rapid distribution phase with a volume of distribution of
0.66 6 0.25 L/kg and an elimination half-life of 46 6
21 min. In patients receiving two doses, baseline serum
levels of bFGF were higher before the second dose of bFGF
compared with day 1 (Table 2). The area of distribution
under the curve demonstrated a dose response relationship
(Fig. 1).
Calf blood flow. PLACEBO PATIENTS. The absolute
changes in flow are shown in Table 3. One placebo patient
had marked improvement in flow at 1 month (Fig. 2), with
decrease below baseline at seven months (1.93, 3.43 and
1.02 mL/min/dL, respectively). A second placebo patient,
who was hypertensive and diabetic, had a decrease in systolic
blood pressure by 23 mm Hg between the first and second
flow measurements and changes in medications that were
made for clinical reasons before the final measurement. This
patient’s flow at baseline, one month and five months was
0.43, 2.05 and 1.54 mL/min/dL. Despite these heteroge-
nous responses at 1 month, calf blood flow in the placebo
group did not change significantly between baseline and six
months (p 5 0.27).
BFGF-TREATED PATIENTS. Resting calf blood flow im-
proved significantly in bFGF-treated patients (Table 3).
The mean percent change in calf blood flow and vascular
resistance measured at one and six months in bFGF-treated
patients is shown in Figure 3. Combining the one- and
two-dose groups, the nine bFGF-treated patients had a
66 6 26% increase in calf blood flow at one month and a
further significant increase of 153 6 51% at six months (p ,
0.05, one vs. six months); vascular resistance decreased by
39 6 7% and 54 6 9% at one and six months (p , 0.0001).
Symptoms. Of the four placebo-treated patients, one re-
ported marked improvement in claudication and walking
distances at one month (blood flow in the treated leg
improved as well, Fig. 2), with worsening to baseline at
seven months. Three of the five patients in the one-dose
bFGF group, and three of the four patients in the two-dose
bFGF group, reported marked symptomatic improvement
at one month. No patient reported worsening of symptoms.
DISCUSSION
Previous studies of angiogenic factors and significance of
this study. There is a significant body of animal data
demonstrating proof of concept of salutary effect of peptide
growth factors in hind limb and myocardial ischemia, and
multiple phase 1 and early phase II trials are in progress.
Recent phase 1 studies have suggested tolerability of vascu-
lar endothelial growth factor (VEGF) gene transfer (15–
17), intracoronary VEGF protein (18), intramyocardial
acidic FGF protein (19) and intracoronary (20) and perivas-
cular (21) bFGF. Gene transfer of plasmid DNA encoding
VEGF has shown favorable results in patients with critical
limb ischemia in an uncontrolled open-label study (22). To
our knowledge, this is the first report of a randomized,
double-blind, placebo-controlled study of bFGF adminis-
tration in humans with peripheral vascular disease. We have
shown that intra-arterial bFGF is well-tolerated and free of
significant adverse effects in subjects with intermittent
claudication.
Pharmacokinetics of bFGF. We found that the acute
hypotensive effects of bFGF can be mitigated by slowing the
rate of infusion. The serum half-life was 46 min, in keeping
with our preclinical studies (7). Basic fibroblast growth
factor had a small volume of distribution, indicating that it
is not extensively tissue-bound. However, in the group
receiving two doses, the level of bFGF was higher before the
Figure 1. Area under the concentration-time curve or measure of total
exposure to basic fibroblast growth factor demonstrated a dose-response
relationship.
Table 2. Pharmakokinetics of bFGF
bFGF Dose/Regimen 10 mg/kg 30 mg/kg
30 mg/kg 3 2
First Dose Second Dose
baseline (bFGF) (pg/mL) 32 6 19 78 6 39 ,10 151 6 16
peak (bFGF) (ng/mL) 29.1 6 2.0 57.4 6 9.5 47.2 6 9.3 61.5 6 20.6
AUC (ng* min/mL) 634 6 104 1325 6 594 3560 6 511
t 1⁄2 (min) 32 6 3 42 6 9 73 6 23
Serum levels of bFGF were quantified by ELISA at 1, 3, 5, 10, 20, 30, 60, 120 and 180 min after infusion. Serum bFGF levels
peaked at 1 min after infusion. Basic fibroblast growth factor had a rapid distribution phase with a volume of distribution of
0.66 6 0.25 L/kg and an elimination half-life of 46 6 21 min.
AUC 5 the area under the concentration-time curve; bFGF 5 basic fibroblast growth factor.
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second dose compared with baseline, suggesting the pres-
ence of a reservoir for bFGF, likely the vascular subendo-
thelial matrix (23), with slow release of the peptide into the
circulation over time.
Potential toxicity of bFGF. Basic fibroblast growth factor
has the potential to induce a nephropathy with proteinuria
at higher doses or with repeated administration over time
(24). We were able to show that two doses of 30 mg/kg of
bFGF did not have appreciable effects on proteinuria or
serum creatinine levels in our patients. Although diabetics
were included, larger numbers of patients are needed before
a deleterious effect on renal function can be safely ruled out
in diabetics and in patients with proteinuria exceeding 200
mg/24 h. Endothelial growth factors have been implicated
as mediators of intraocular neovascularization (25,26). In
our study of patients with normal retinae at baseline and in
individuals with mild to moderate nonproliferative retinop-
athy (three patients enrolled in the study had nonprolifera-
tive retinopathy), bFGF did not induce new vessel forma-
tion. The effects of bFGF on hypoxic or ischemic retinae or
on diabetic proliferative retinopathy remain unknown.
Thrombocytopenia that occurred in a bFGF-treated patient
was transient and asymptomatic, consistent with preclinical
safety data with bFGF (7,8).
Calf blood flow changes with bFGF. This was a phase I
study not primarily designed to assess efficacy. Calf blood
flow was measured as an exploratory secondary end point.
We found that one and two intra-arterial doses of bFGF at
30 mg/kg improved calf blood flow in the treated leg. This
was accompanied by subjective improvement in symptoms
in a majority of treated patients, consistent with a biologic
effect. There appears to be a dose-response relationship
between the dose of bFGF and calf blood flow. However,
the differences between the two doses were not statistically
significant, a fact probably due to the small numbers of
patients studied. Calf blood flow in the treated patients
continued to improve three to seven months after treatment,
suggesting that activities of daily living may have provided
an ischemic milieu that sustained and improved the angio-
genic effect of bFGF with time. The acute vasodilatory
effects of bFGF could have contributed to collateral devel-
opment (27); however, other vasodilators have failed to
produce consistent effects on collateral growth (28,29).
These results on calf blood flow are preliminary and cannot
be considered definitive; however, the results are clinically
encouraging and warrant further study.
Placebo component in angiogenic trials. A large placebo
response is common in claudication trials. In a review of 75
Figure 2. Resting calf blood flow in all placebo and bFGF-treated patients at baseline and 1 month. The greatest improvement in calf blood flow occurred
in a placebo patient. bFGF 5 basic fibroblast growth factor.
Table 3. Resting Calf Blood Flow (ml/min/dl)
Baseline 1 Month 6 Months
p (Baseline vs. 6
Months)
Placebo 1.29 6 0.33 2.15 6 0.44 1.35 6 0.17 0.27
30 mg/kg 3 1 1.11 6 0.21 1.44 6 0.23 2.09 6 0.55 0.046
30 mg/kg 3 2 0.60 6 0.10 1.10 6 0.09 1.91 6 0.06 ,0.001
Flow improved significantly between 1 and 6 months in bFGF-treated patients.
bFGF 5 basic fibroblast growth factor.
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studies, 84% of open-label or uncontrolled studies suggested
benefit from drug treatment, whereas only 32% of placebo-
controlled trials reported improvement (2). Our study illus-
trates the heterogeneity of responses in this patient popu-
lation. Indeed, the patient manifesting the greatest
improvement in calf blood flow in our study was a placebo
patient (Fig. 2). Recently, the placebo response was well-
illustrated in coronary artery disease (CAD) patients receiv-
ing intravascular VEGF (18). Several phase I/II angiogenic
trials are being planned or are under way in CAD and PVD
patients, and the need for placebo-controlled studies is
evident.
The best approach to angiogenic drug delivery (recombi-
nant protein vs. gene therapy) is unclear, and the long-term
safety of these agents is unknown.
Conclusions. Our phase I study indicates that intra-
arterial bFGF is feasible and well-tolerated in PVD patients
and free of significant adverse effects at short-term follow-
up. The preliminary findings of a salutary effect on calf
blood flow require confirmation in a larger trial sufficiently
powered to determine efficacy.
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